Status:
UNKNOWN
Validation Study of Uromonitor in High Risk Microhematuria Patients
Lead Sponsor:
Clinica Universidad de Navarra, Universidad de Navarra
Collaborating Sponsors:
IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto
Conditions:
Bladder Cancer
Eligibility:
All Genders
40+ years
Brief Summary
Men over 40 years of age, and women over 50, smokers or former smokers with a smoking rate greater than 10 packs/year and the presence of microhematuria \>25 red blood cells per field in the microscop...
Detailed Description
1. Title: Validation study of Uromonitor in the early diagnosis of bladder cancer in high-risk patients with microhematuria. Version: 2.0. March 6, 2022. Main author: Felipe Villacampa Aubá. Depar...
Eligibility Criteria
Inclusion
- Inclusion Criteria (all conditions must be certified):
- Men over 40 years of age or Women over 50 years of age.
- Smokers or former smokers
- Smoking rate \>10 packs/year
- Microhematuria with \>25 red blood cells per hpf.
- Exclusion Criteria: (any of them):
- Patients who refuse to undergo cystoscopy.
- Patients who refuse or cannot perform imaging tests of the upper section due to allergy or chronic kidney disease.
- History of macroscopic hematuria.
- History of microscopic hematuria already known and studied.
- Known cause of microhematuria: e.g. urinary infection, bladder lithiasis
- Patients who refuse to participate in the study.
Exclusion
Key Trial Info
Start Date :
May 2 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2024
Estimated Enrollment :
343 Patients enrolled
Trial Details
Trial ID
NCT05344937
Start Date
May 2 2022
End Date
May 1 2024
Last Update
May 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinica Universidad de Navarra
Madrid, Spain, 28027